In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Oppenheimer analyst Brian Schwartz increased the price target on Freshworks Inc (NASDAQ:FRSH) to $24 from $22, while retaining an Outperform rating on the shares. According to InvestingPro data, ...

(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

Oppenheimer analyst Christopher Glynn maintained a Perform rating for Generac Holdings (NYSE:GNRC) following the company's fourth-quarter earnings report. According to InvestingPro data, Generac is ...

Reports of a potential merger of Cboe Global Markets' (CBOE) and CME Group (CME) could revive on perceived lack of revenue ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “market perform” rating restated by analysts at Oppenheimer in a research note issued to investors on Monday, MarketBeat.com reports ...

Oppenheimer initiated coverage of IBM (IBM) with an Outperform rating and $320 price target The firm’s bullish stance is based on the view ...

AUM and trading activity drives Oppenheimer's wealth management business. Read why we remain bullish on OPY stock.

Cillian Murphy’s dedication to Oppenheimer went beyond acting—he learned 30,000 words of Dutch, followed a brutal diet, and ...

Benny Safdie is the latest actor to join the cast of The Odyssey, the next movie from Christopher Nolan, according to The ...

Oppenheimer downgraded Apple from "outperform" to "perform" because it is struggling to adapt to a competitive AI landscape.

Director Christopher Nolan is set to reunite with one of the stars from his multi-award-winning film Oppenheimer for his next ...